Kangstem Biotech Co., Ltd. (KOSDAQ:217730)

South Korea flag South Korea · Delayed Price · Currency is KRW
4,075.00
-35.00 (-0.85%)
At close: Apr 27, 2026
67.70%
Market Cap 385.15B
Revenue (ttm) 3.57B
Net Income (ttm) -10.48B
Shares Out 94.05M
EPS (ttm) -151.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 784,430
Average Volume 2,121,041
Open 4,100.00
Previous Close 4,110.00
Day's Range 4,000.00 - 4,175.00
52-Week Range 1,080.00 - 4,690.00
Beta 0.29
RSI 61.19
Earnings Date May 11, 2026

About Kangstem Biotech

Kangstem Biotech Co., Ltd. a biopharmaceutical company, develops stem cell therapeutic products for rare and incurable diseases. The company's stem cell therapy products include Furestem-AD for treatment of subacute and chronic atopic dermatitis; Furestem-RA to treat rheumatoid arthritis; and Furestem-CD for treatment of active crohn’s disease. It also provides stem cell conditioned media, such as umbilical cord blood-derived stem cell conditioned media that includes epidermal, vascular endothelium, keratinocyte, hepatocyte, transforming, and p... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2010
Employees 97
Stock Exchange KOSDAQ
Ticker Symbol 217730
Full Company Profile

Financial Performance

In 2025, Kangstem Biotech's revenue was 3.57 billion, a decrease of -53.88% compared to the previous year's 7.75 billion. Losses were -10.48 billion, 36.7% more than in 2024.

Financial Statements

News

There is no news available yet.